The incidence of pancreatic cancer is on the rise [1, 2]. Surgery has traditionally been considered the cornerstone in the management of resectable pancreatic cancer [3, 4]. However, we now know that improved outcomes can be achieved by combining surgery with chemotherapy under the broad umbrella of multimodality therapy [5, 6]. This multimodality approach is best suited to only 20% of patients with pancreatic cancer who present when the disease is still amenable to surgical resection. The vast majority of patients, though, present with advanced disease where the aim of therapy is disease control through efforts directed at retarding its progression [7–9].
|Title of host publication||Surgical Diseases of the Pancreas and Biliary Tree|
|Editors||Savio Barreto, John Windsor|
|Number of pages||43|
|Publication status||Published - 2018|
- pancreatic cancer